Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Amphenol Corporation (NYSE: APH), a key player in electronic connectors, received concurrent price target increases from Seaport Research and Citi. While analysts highlight growth potential, the stock's post-earnings dip underscores a cautious market stance toward the company's traditionally conservative guidance.
Needham raises Nova Ltd. (NVMI) to Buy with a $500 price target, citing improving industry conditions and the company's strategic position in China's memory market. The upgrade follows a similar bullish move by Bank of America earlier in January.
Oppenheimer and Wells Fargo have raised price targets for Monolithic Power Systems (MPWR), highlighting robust demand from the automotive and artificial intelligence sectors as key growth drivers ahead of the company's quarterly results.
Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.
BofA Securities has trimmed its price target for Uber Technologies, citing near-term uncertainties in the autonomous vehicle sector, even as the company launches a new internal data initiative aimed at accelerating AV development.
A months-long advocacy campaign criticizing Hannaford's pricing and animal welfare policies has gained little traction among Maine shoppers, many of whom remain loyal to the dominant grocer despite concerns over affordability.
Brand incubator Maesa is betting on the growing body care category with the launch of Ontu, a new line bringing high-performance, facial-inspired formulas to Target shelves at accessible price points, capitalizing on shifting consumer skincare rituals.
Private equity firm Exponent has halted the auction of UK accounting group Xeinadin after potential buyers refused to meet its £1bn valuation, signaling potential headwinds for deal-making in the professional services sector.
While analyst price targets often paint a rosy picture, a deeper look reveals which recommendations are backed by solid business trends and which may be overly optimistic. We examine one fintech disruptor and one industrial stalwart favored by the Street, alongside a retailer facing significant headwinds.
While analyst price targets often paint a rosy picture, a closer look reveals a more nuanced reality. We examine one favored stock with solid fundamentals and two others where the Street's optimism may be overlooking critical risks.
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
In a market where Wall Street analysts often shy away from bearish calls, stark price targets on certain stocks raise red flags. We spotlight one contrarian pick and two companies facing significant headwinds.
Despite outperforming key benchmarks, APA Corporation faces a wall of analyst skepticism. With shares already trading above the average price target, the energy producer's disciplined strategy collides with muted expectations for near-term gains.
Satellite communications provider Viasat (VSAT) saw its shares hit a new 52-week peak of $46.49, capping a remarkable 12-month rally. The surge follows a significant price target upgrade from Morgan Stanley and the successful launch of a key global network for government clients.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
Tesla's stock is navigating turbulent waters, with a recent one-day surge contrasting sharply against a weaker quarterly performance. As the EV pioneer's share price hovers above some analyst targets, investors are left weighing its ambitious robotaxi and AI-driven future against more conservative valuation models.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
